ReviewTranslational research : the journal of laboratory and clinical medicine2018
Liquid biopsies for hepatocellular carcinoma.
Review in Translational research : the journal of laboratory and clinical medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Predictive value of biomarkers for lenvatinib in hepatocellular carcinoma.Therapeutic advances in medical oncology · 2025Review
- An Investigation into Cell-Free DNA in Different Common Cancers.Molecular biotechnology · 2024Review
- Genetic screening of liver cancer: State of the art.World journal of hepatology · 2024Review
- Depleting circ_0088364 restrained cell growth and motility of human hepatocellular carcinoma via circ_0088364-miR-1270-COL4A1 ceRNA pathway.Cell cycle (Georgetown, Tex.) · 2022Article
- Circulating messenger RNA variants as a potential biomarker for surveillance of hepatocellular carcinoma.Frontiers in oncology · 2022Article
- Detection ofDiagnostics (Basel, Switzerland) · 2021Article
- Role of ssDNA as a Noninvasive Indicator for the Diagnosis and Prognosis of Hepatocellular Carcinoma: An Exploratory Study.Disease markers · 2021Article
- Lack of MOF Decreases Susceptibility to Hypoxia and Promotes Multidrug Resistance in Hepatocellular Carcinoma via HIF-1α.Frontiers in cell and developmental biology · 2021Article
- Hepatitis B virus preS2Δ38-55 variants: A newly identified risk factor for hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2020Article
- Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma.Clinical and experimental medicine · 2020Review
- Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?Journal of clinical medicine · 2020Review
- Circulating tumor cells in the clinical cancer diagnosis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Review
- Novel Liquid Biopsy Test Based on a Sensitive MethylatedHepatology communications · 2020Article
- Circular RNA hsa_circ_0000517 modulates hepatocellular carcinoma advancement via the miR-326/SMAD6 axis.Cancer cell international · 2020Article
- DNA hypermethylation in disease: mechanisms and clinical relevance.Epigenetics · 2019Review
- Identification of Serum miRNA-423-5p Expression Signature in Somatotroph Adenomas.International journal of endocrinology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is the world's second leading cause of cancer death; 82.4% of patients die within 5 years. This grim prognosis is the consequence of a lack of effective early detection tools, limited treatment options, and the high frequency of HCC recurrence. Advances in the field of liquid biopsy hold great promise in improving early detection of HCC, advancing patient prognosis, and ultimately increasing the survival rate. In an effort to address the current challenges of HCC screening and management, several studies have identified and evaluated liver-cancer-associated molecular signatures such as genetic alterations, methylation, and noncoding RNA expression in the form of circulating biomarkers in body fluids and circulating tumor cells of HCC patients. In this review, we summarize the recent progress in HCC liquid biopsy, organized by the intended clinical application of the reported study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.